Monday, 18 Mar 2019

You are here

MRI Imaging for Sacroiliitis Requires Bone Marrow Edema for Reliability

de Winter and colleagues from the Netherlands have reported on magnetic resonance imaging (MRI) of the sacroiliac (SI) joints of healthy subjects, patients with axial spondyloarthritis (SpA), runners and those with chronic back pain, and found a high incidence of sacroiliitis in many, but that deep bone marrow edema was most specific for those with axial SpA.

Three trained, experienced MRI readers assessed the SI joints of 172 subjects (47 healthy controls without low back pain (LBP), 47 axial SpA, 47 controls with chronic back pain, 7 with postpartum back pain, and 24 frequent runners) and scored these according to ASAS and SPARCC methods. The results are shown below:

 nHLA-B27+MRI Sacroiliitis

SPARCC Sacroiliitis

Deep Bone Marrow Edema

Axial SpA4774,5%91.5%97.7%89.4%
Normal controls47023.4%25.5%0
Chronic LBP4706.4%10.6%0
Post-partum LBP70 57.1%57.1%14.3%
Runners24012.5% 16.7%0

While some evidence of MRI sacroiliits may be found in minority of those with LBP, it appears that only deep (extensive) bone marrow edema lesions are most specific for axial SpA patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed. 

AAD/NPF Guidelines on Biologic Use in Psoriasis

Menter and colleagues from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) have published their expert consensus guidelines for the use of biologics in psoriasis.

Dermatology Guidelines for Psoriatic Comorbidities

The JAAD has published joint guidelines from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) on the approach, management and dermatolgist roles for select comorbid conditions. 

Early TNF inhibition in Early Psoriatic Arthritis

A small, double-blind, randomised, placebo-controlled trial in early psoriatic arthritis (PsA) has shown that first-line use of golimumab and methotrexate (MTX) is superior to MTX alone in inducing remission in PsA.